ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer

This publication has 36 references indexed in Scilit:

• Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer
  Oncogene, 2000
• Suppression of transforming growth factor-β-induced apoptosis through a phosphatidylinositol 3-kinase/Akt-dependent pathway
  Oncogene, 1998
• Multiple splicing variants of the estrogen receptor are present in individual human breast tumors
  The Journal of Steroid Biochemistry and Molecular Biology, 1996
• Relation of oestradiol-mediated growth stimulation with the expression of c-erbB-2 protein in xenotransplanted oestradiol-receptor-positive and -negative breast carcinomas
  Zeitschrift für Krebsforschung und Klinische Onkologie, 1996
• c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer
  European Journal Of Cancer, 1995
• Simultaneous analysis of c‐erbB‐2 expression and DNA content in breast cancer using flow cytometry
  Cytometry, 1994
• ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer
  Cancer Letters, 1994
• Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failure
  The Journal of Steroid Biochemistry and Molecular Biology, 1990
• Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
  Science, 1987
• Nonparametric Estimation from Incomplete Observations
  Journal of the American Statistical Association, 1958